Two-year single-center real-life data of Tenofovir Disoproxil Fumarate treatment for chronic hepatitis B patients in Taiwan

Shou-Wu Lee, Teng-Yu Lee, Sheng-Shun Yang, Hong-Zen Yeh, Chi-Sen Chang

Abstract


Aim: Chronic infection with hepatitis B virus (CHB) is a worldwide disease. The aim of this study was to evaluate the treatment efficacy and renal tolerability of Tenofovir disoproxil fumarate (TDF) in patients with CHB. Method: Data from patients were retrospectively collected from January 2012 to September 2014. The inclusion criteria included CHB, serum HBV DNA > 2000 IU/ml, high serum alanine aminotransferase (ALT), and persistent use of TDF for at least one year. The exclusion criteria included HCV or HIV coinfection. The therapeutic efficacy was recorded at screening and every 6 months thereafter. Results: Among all 100 enrolled subjects, 28 and 24 patients were HBe-positive and treatment-experienced, respectively. The 2-year biochemical response (ALT less than 40 U/L) was 95% to 100%, virologic response (HBV DNA < 20 IU/ml) was 86% to 98%, and serologic response (HBeAg seroloss) was 33%. No cases with HBsAg clearance were detectable. No significant difference existed between treatment-naïve and -experienced patients, but those with positive HBe had a poor virological response compared with the negative HBe group (P=0.043). There was no significant change in renal function. Conclusion: TDF treatment was considered as a efficient, safe and well tolerated therapy to CHB individuals.


Keywords


hepatitis B; Tenofovir

References


Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97–107.

Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335–352.

Chen CJ, Iloege UH, Yang HI. Serum hepatitis B virus DNA as a predictor of the development of cirrhosis and hepatocellular carcinoma. Curr Hepat Rep 2007;6:9–16.

European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227–242.

Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50: 661–662.

Duarte-Rojo A, Heathcote J. Efficacy and safety of tenofovir disoproxil fumerate in patients with chronic hepatitis B. Therap Adv Gastroenterol 2010; 3: 107–119.

Marcellin, P., Heathcote, E.J., Buti, M., Gane, E., de Man, R.A., Krastev, Z. et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442–2455.

Heathcote EJ, Gane E, deMan R, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103), preliminary analysis. Hepatology 2008;48(Suppl 1):376A.

Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011;140:132–143.

Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology 2013;58:505–513.

Carey I, Nguyen H-L, Joe D, et al. De-novo antiviral therapy with nucleos(t)ide analogues in real-life pateints with chronic hepatitis B infection: comparison of virological responses between lamivudine+adefovir, entecavir vs. tenofovir therapy. Hepatology 2011; 54(Suppl 1): Abstract 1396.

Lampertico P, Soffredini R, Vigano M, et al. 2 year effectiveness and safety of tenofovir in 302 NUC-naive patients with chronic hepatitis B: a multicenter European study in clinical practice. Hepatology 2011;54(Suppl 1):Abstract 1433.

Lin B, Ha NB, Liu A, Trinh HN, Nguyen HA, Nguyen KK, Ahmed A, Keeffe EB, Garcia RT, Garcia G, Nguyen MH. Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice. J Gastroenterol Hepatol 2013; 28: 855–860.

Petersen J, Heyne R, Mauss S, Schlaak J, Schiffelholz W, Eisenbach C, Hartmann H. Effectiveness of tenofovir for chronic hepatitis B in field practice–2 year interim results from the prospective German multicenter non-interventional study (GEMINIS). J Hepatol 2013;58 Suppl 1:Abstract 768.

Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, Schall RA, Flaherty JF, Martins EB, Charuworn P, Kitrinos KM, Subramanian GM, Gane E, Marcellin P. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60:1457–64.

Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, Desmond PV, Roberts SK, Locarnini S, Bowden S, Angus PW. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut. 2011;60:247–254.

Lim YS, Yoo BC, Byun KS, Kwon SY, Kim YJ, An J, Lee HC, Lee YS. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. Gut. 2015 Mar 23. [Epub ahead of print]

Heathcote EJ, Gane EJ, de Man RA et al. Long-term (4 year) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAg positive patients with chronic hepatitis B (study 103). Hepatology 2010;52(Suppl 1):Abstract 477.

Hezode C, Causse X, Larrey D, Ouzan D, Pageaux GP, Truchi R, Pauwels A, Guyader D, De L’edinghen V, Zoulim F, Zarski JP, Cadranel JF, Tilliet V, Libert1 O, Stern C, Marcellin P, Vireal Group.Virological response and tolerance of tenofovir DF (TDF) in the elderly is similar to younger patients in real life practice. J Hepatol. 2013;58 Suppl 1:Abstract 748.


Full Text: PDF HTML

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.